{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T12:20:11Z","timestamp":1782303611965,"version":"3.54.5"},"reference-count":285,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013487","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T14:31:22Z","timestamp":1574692282000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis"],"prefix":"10.1002","volume":"2020","author":[{"given":"Vanessa","family":"Piechotta","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Jakob","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Langer","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Monsef","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Scheid","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Stem Cell Transplantation Program; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise J","family":"Estcourt","sequence":"additional","affiliation":[{"name":"Haematology\/Transfusion Medicine; NHS Blood and Transplant; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunday","family":"Ocheni","sequence":"additional","affiliation":[{"name":"Department of Haematology & Immunology; University of Nigeria; Enugu Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Theurich","sequence":"additional","affiliation":[{"name":"Department of Medicine III; University Hospital LMU, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen; Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Kuhr","sequence":"additional","affiliation":[{"name":"Institute of Medical Statistics and Computational Biology; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Scheckel","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"},{"name":"Institute of Health Economics and Clinical Epidemiology; University of Cologne, Faculty of Medicine and University Hospital Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Adams","sequence":"additional","affiliation":[{"name":"Institute of Medical Statistics and Computational Biology; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Skoetz","sequence":"additional","affiliation":[{"name":"Cochrane Cancer, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,11,25]]},"reference":[{"key":"10.1002\/14651858.CD013487-BIB0001|cit1","doi-asserted-by":"crossref","unstructured":"Avet-Loiseau H Hulin C Benboubker L Dimopoulos MA Belch A Reece D Impact of cytogenetics on outcomes of transplant-ineligible patients with newly diagnosed multiple myeloma treated with continuous lenalidomide plus low-dose dexamethasone in the first (MM-020) trial Blood 2015 730","DOI":"10.1182\/blood.V126.23.730.730"},{"key":"10.1002\/14651858.CD013487-BIB0002|cit2","doi-asserted-by":"crossref","unstructured":"Bahlis N Corso A Mugge LO Shen ZX Desjardins P Stoppa AM Impact of response in patients (pts) with stem cell transplant (SCT)-ineligible newly diagnosed multiple myeloma (NDMM) treated with continuous lenalidomide + low-dose dexamethasone (Rd) in the first trial Clinical Lymphoma, Myeloma and Leukemia 2015 e56","DOI":"10.1016\/j.clml.2015.07.196"},{"key":"10.1002\/14651858.CD013487-BIB0003|cit3","unstructured":"Bahlis N Corso A Shen ZX Desjardins P Stoppa AM Assessing the benefit of continuous treatment in the first trial (MM-020): impact of response in patients with transplant-ineligible newly diagnosed multiple myeloma Haematologica 2015 85 6"},{"issue":"11","key":"10.1002\/14651858.CD013487-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1038\/leu.2017.111","article-title":"Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial","volume":"31","author":"Bahlis","year":"2017","journal-title":"Leukemia"},{"issue":"10","key":"10.1002\/14651858.CD013487-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013487-BIB0006|cit6","doi-asserted-by":"crossref","unstructured":"Delforge M Minuk L Eisenmann JC Arnulf B Canepa L Fragasso A Health-related quality of life (HRQOL) in patients (pts) with newly diagnosed multiple myeloma (NDMM): the first trial Haematologica 2014 109 10","DOI":"10.1200\/jco.2014.32.15_suppl.8516"},{"issue":"6","key":"10.1002\/14651858.CD013487-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3324\/haematol.2014.120121","article-title":"Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide","volume":"100","author":"Delforge","year":"2015","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD013487-BIB0008|cit8","unstructured":"Dimopoulos M Cheung M Roussel M Liu T Gamberi B Kolb B Impact of renal impairment on outcomes after treatment with lenalidomide and low-dose dexamethasone in patients with newly diagnosed multiple myeloma: first trial results Haematologica 2015 83 4"},{"issue":"3","key":"10.1002\/14651858.CD013487-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3324\/haematol.2015.133629","article-title":"Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma","volume":"101","author":"Dimopoulos","year":"2016","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD013487-BIB0010|cit10","doi-asserted-by":"crossref","unstructured":"Facon T Dimopoulos MA Dispenzieri A Catalano JV Belch A Cavo M Final analysis of overall survival from the first trial Blood 2016","DOI":"10.1182\/blood.V128.22.241.241"},{"issue":"3","key":"10.1002\/14651858.CD013487-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","article-title":"Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma","volume":"131","author":"Facon","year":"2018","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013487-BIB0012|cit12","unstructured":"Facon T Dimopoulos MA Dispenzieri A Catalano JV Belch A Hulin C Lenalidomide+low-dose dexamethasone (RD) VS. melphalanprednisone-thalidomide (MPT) in newly diagnosed multiple myeloma (NDMM) patients (PTS): the first trial Haematologica 2014 220 1"},{"key":"10.1002\/14651858.CD013487-BIB0013|cit13","doi-asserted-by":"crossref","unstructured":"Facon T Dimopoulos MA Hulin C Benboubker L Belch A Ludwig H Updated overall survival (OS) analysis of the FIRST study: lenalidomide plus low-dose dexamethasone (Rd) continuous vs melphalan, prednisone, and thalidomide (MPT) in patients (Pts) With newly diagnosed multiple myeloma (NDMM) Clinical Lymphoma, Myeloma and Leukemia 2015 e134","DOI":"10.1016\/j.clml.2015.07.330"},{"key":"10.1002\/14651858.CD013487-BIB0014|cit14","doi-asserted-by":"crossref","unstructured":"Facon T Dimopoulos MA Hulin C Benboubker L Belch A Ludwig H Updated overall survival analysis of the first study: continuous lenalidomide plus low-dose dexamethasone vs melphalan, prednisone, and thalidomide in patients with newly diagnosed multiple myeloma Haematologica 2015 3","DOI":"10.1016\/j.clml.2015.07.330"},{"key":"10.1002\/14651858.CD013487-BIB0015|cit15","unstructured":"Facon T Hulin C Dimopoulos MA Belch A Meuleman N Mohty M A frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated with continuous lenalidomide plus low-dose dexamethasone in the first (MM-020) trial Haematologica 2016 258 9"},{"key":"10.1002\/14651858.CD013487-BIB0016|cit16","doi-asserted-by":"crossref","unstructured":"Facon T Hulin C Dimopoulos MA Belch A Meuleman N Mohty M A frailty scale predicts outcomes of patients with newly diagnosed multiple myeloma who are ineligible for transplant treated with continuous lenalidomide plus low-dose dexamethasone on the first trial Blood 2015 4239","DOI":"10.1182\/blood.V126.23.4239.4239"},{"key":"10.1002\/14651858.CD013487-BIB0017|cit17","doi-asserted-by":"crossref","unstructured":"Facon T Hulin C Dimopoulos MA Belch A Reece DE Catalano JV FIRST study: updated overall survival (OS) in stem cell transplant (SCT)-ineligible newly diagnosed multiple myeloma (NDMM) patients (pts) treated with continuous lenalidomide plus low-dose dexamethasone (Rd) vs melphalan, prednisone, and thalidomide (MPT) Journal of Clinical Oncology 2015","DOI":"10.1200\/jco.2015.33.15_suppl.8524"},{"key":"10.1002\/14651858.CD013487-BIB0018|cit18","doi-asserted-by":"crossref","unstructured":"Facon T Continuous therapy for elderly newly diagnosed multiple myeloma Clinical Lymphoma, Myeloma and Leukemia 2015 e28","DOI":"10.1016\/j.clml.2015.08.052"},{"issue":"30","key":"10.1002\/14651858.CD013487-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1200\/JCO.2016.66.7295","article-title":"Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or melphalan, prednisone, and thalidomide in the randomized, phase III FIRST trial","volume":"34","author":"Hulin","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013487-BIB0020|cit20","unstructured":"Hulin C Shustik C Belch A Petrucci M Duhrsen U Lu J Effect of age on efficacy and safety outcomes in patients with newly diagnosed multiple myeloma receiving lenalidomide and low-dose dexamethasone (RD): the first trial Haematologica 2015 152 3"},{"key":"10.1002\/14651858.CD013487-BIB0021|cit21","doi-asserted-by":"crossref","unstructured":"Hulin C Shustik C Belch A Petrucci MT Duhrsen U Lu J Continuous treatment with lenalidomide and low-dose dexamethasone for patients with transplant-ineligible newly diagnosed multiple myeloma in the first trial: impact of age Clinical Lymphoma, Myeloma and Leukemia 2015 e130 1","DOI":"10.1016\/j.clml.2015.07.324"},{"key":"10.1002\/14651858.CD013487-BIB0022|cit22","doi-asserted-by":"crossref","unstructured":"Lu J Lee JH Huang SY Qiu L Lee JJ Liu T Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the first trial Blood 2015 4240","DOI":"10.1182\/blood.V126.23.4240.4240"},{"key":"10.1002\/14651858.CD013487-BIB0023|cit23","unstructured":"Lu J Lee JH Huang SY Qiu L Lee JJ Liu T The first trial: analysis of the Asian subgroup of transplant-ineligible patients with newly diagnosed multiple myeloma treated with continuous lenalidomide and low-dose dexamethasone Haematologica 2016 548 9"},{"key":"10.1002\/14651858.CD013487-BIB0024|cit24","doi-asserted-by":"crossref","unstructured":"Weisel K Vogl D Corso A Delforge M Song K Dimopoulos MA Health resource utilization with continuous lenalidomide treatment (TX) in elderly patients with newly diagnosed multiple myeloma (NDMM) Haematologica 2015 24 5","DOI":"10.1016\/j.clml.2015.07.383"},{"issue":"1","key":"10.1002\/14651858.CD013487-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1600-0609.2010.01524.x","article-title":"Addition of thalidomide to oral melphalan\/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group","volume":"86","author":"Beksac","year":"2011","journal-title":"European Journal of Haematology"},{"key":"10.1002\/14651858.CD013487-BIB0026|cit26","doi-asserted-by":"crossref","unstructured":"Durie B Hoering A Rajkumar SV Abidi MH Epstein J Kahanic SP Bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (PTS) with previously untreated multiple myeloma without an intent for immediate Autologous Stem Cell Transplant (ASCT): results of the randomized phase III trial SWOG S0777 Blood 2015 25","DOI":"10.1182\/blood.V126.23.25.25"},{"key":"10.1002\/14651858.CD013487-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013487-BIB0028|cit28","doi-asserted-by":"crossref","unstructured":"Facon T Mary JY Hulin C Benboubker L Attal M Harousseau JL Randomized clinical trial comparing melphalan-prednisone (MP), MP-thalidomide (MP-THAL) and high-dose therapy using melphalan 100 MG\/M\u00fd (MEL100) for newly diagnosed myeloma patients Aged 65-75 years. Interim analysis of the IFM 99-06 Trial on 350 patients Blood 2004 63","DOI":"10.1182\/blood.V104.11.206.206"},{"issue":"9594","key":"10.1002\/14651858.CD013487-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"issue":"22","key":"10.1002\/14651858.CD013487-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","article-title":"Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01\/01 trial","volume":"27","author":"Hulin","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013487-BIB0031|cit31","doi-asserted-by":"crossref","unstructured":"Hulin C Facon T Rodon P Pegourie B Benboubker L Doyen C Melphalan-prednisone-thalidomide (MP-T) demonstrates a significant survival advantage in elderly patients >=75 years with multiple myeloma compared with melphalan-pPrednisone (MP) in a randomized, double-blind, placebo-controlled trial, IFM 01\/01 Blood 2007","DOI":"10.1182\/blood.V110.11.75.75"},{"key":"10.1002\/14651858.CD013487-BIB0032|cit32","doi-asserted-by":"crossref","unstructured":"Hulin C Virion J Leleu X Rodon P Pegourie B Benboubker L Comparison of melphalan-prednisone-thalidomide (MP-T) to melphalan-prednisone (MP) in patients 75 years of age or older with untreated multiple myeloma (MM). Preliminary results of the randomized, double-blind, placebo controlled IFM 01-01 trial Journal of Clinical Oncology 2007 441","DOI":"10.1200\/jco.2007.25.18_suppl.8001"},{"key":"10.1002\/14651858.CD013487-BIB0033|cit33","unstructured":"Iberoamerican protocol with thalidomide in patients with symptomatic newly diagnosed multiple myeloma over 65 years available at: https:\/\/clinicaltrials.gov\/show\/nct01532856"},{"key":"10.1002\/14651858.CD013487-BIB0034|cit34","doi-asserted-by":"crossref","unstructured":"Crusoe E Maiolino A Bittencourt R Fantl DB MacIel J Sampaio M A phase III study comparing thalidomide\/cyclophosphamide\/dexa vs thalidomide\/dexa vs thalidomide\/melphalan\/prednisone in de novo multiple myeloma patients not eligible for ASCT Blood 2011","DOI":"10.1182\/blood.V118.21.5117.5117"},{"key":"10.1002\/14651858.CD013487-BIB0035|cit35","doi-asserted-by":"crossref","unstructured":"Hungria V Crusoe E Maiolino A Bittencourt R Fantl D Quero A A phase III study comparing thalidomide\/cyclophosphamide\/ dexa vs thalidomide\/dexa vs thalidomide\/melphalan\/prednisone in de novo multiple myeloma patients not eligible for ASCT: preliminary analysis Haematologica 2010 148","DOI":"10.1182\/blood.V118.21.5117.5117"},{"issue":"2","key":"10.1002\/14651858.CD013487-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00277-015-2537-2","article-title":"Phase 3 trial of three thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant-eligible","volume":"95","author":"Hungria","year":"2016","journal-title":"Annals of Hematology"},{"key":"10.1002\/14651858.CD013487-BIB0037|cit37","doi-asserted-by":"crossref","unstructured":"Fonseca R Rajkumar SV Consolidation therapy with bortezomib\/lenalidomide\/ dexamethasone versus bortezomib\/dexamethasone after a dexamethasone-based induction regimen in patients with multiple myeloma: a randomized phase III trial Clinical Lymphoma and Myeloma 2008 8 5 315 7","DOI":"10.3816\/CLM.2008.n.046"},{"key":"10.1002\/14651858.CD013487-BIB0038|cit38","doi-asserted-by":"crossref","unstructured":"Jacobus SJ Rajkumar SV Weiss M Stewart AK Stadtmauer EA Callander NS Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen Blood Cancer Journal 2016 6 7 e448","DOI":"10.1038\/bcj.2016.55"},{"key":"10.1002\/14651858.CD013487-BIB0039|cit39","unstructured":"Katsuoka Y Kato Y Omoto E Sasaki O Kimura H Meguro K Phase ii trial of bortezomib based regimen for transplant-ineligible multiple myeloma-tomato study Clinical Lymphoma, Myeloma and Leukemia 2013 S148"},{"key":"10.1002\/14651858.CD013487-BIB0040|cit40","unstructured":"Kim YK Lee JJ Sohn SK Shin HJ Lee SR Shim HJ Efficacy and safety of thalidomide and dexamethasone combination with or without cyclophosphamide in patients with newly diagnosed multiple myeloma Haematologica 2007 411 2"},{"key":"10.1002\/14651858.CD013487-BIB0041|cit41","doi-asserted-by":"crossref","unstructured":"Ludwig H Drach J Tothova E Gisslinger H Linkesch W Jaksic B Thalidomide-dexamethasone (TD) versus melphalan-prednisolone (MP) as first line treatment in elderly patients with multiple myeloma (MM): an interim analysis Onkologie 2005 14 5","DOI":"10.1200\/jco.2005.23.16_suppl.6537"},{"issue":"15","key":"10.1002\/14651858.CD013487-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1182\/blood-2008-07-169565","article-title":"Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma","volume":"113","author":"Ludwig","year":"2009","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013487-BIB0043|cit43","doi-asserted-by":"crossref","unstructured":"Ludwig H Tothova E Hajek R Drach J Adam Z Labar B Thalidomide-dexamethasone vs. melphalan-prednisone as first line treatment and thalidomide-interferon vs. interferon maintenance therapy in elderly patients with multiple myeloma Blood 2007 163a","DOI":"10.1182\/blood.V110.11.529.529"},{"key":"10.1002\/14651858.CD013487-BIB0044|cit44","unstructured":"Ludwig H Tothova E Hajek R Drach J Labar B Egyed M Thalidomide-dexamethasone versus melphalan-prednisolone as first line treatment in elderly patients with multiple myeloma: second interim analysis Haematologica 2007 166"},{"key":"10.1002\/14651858.CD013487-BIB0045|cit45","doi-asserted-by":"crossref","unstructured":"Ludwig HL Drach J Tothova E Gisslinger H Linkesch W Jaksic B Thalidomide-dexamethasone versus melphalan-prednisolone as first line treatment in elderly patients with multiple myeloma: an interim analysis European Hematology Association 2005","DOI":"10.1200\/jco.2005.23.16_suppl.6537"},{"key":"10.1002\/14651858.CD013487-BIB0046|cit46","doi-asserted-by":"crossref","unstructured":"Ludwig HL Drach J Tothova E Gisslinger H Linkesch W Jaksic B Thalidomide-dexamethasone versus melphalan-prednisolone as first line treatment in elderly patients with multiple myeloma: an interim analysis Haematologica 2005 158","DOI":"10.1200\/jco.2005.23.16_suppl.6537"},{"key":"10.1002\/14651858.CD013487-BIB0047|cit47","doi-asserted-by":"crossref","unstructured":"Bringhen S Offidani M Musto P Liberati AM Benevolo G Cascavilla N Long term outcome of lenalidomide-dexamethasone (RD) vs melphalan-lenalidomide-prednisone (MPR) vs cyclophosphamide-prednisone-lenalidomide (CPR) as induction followed by Blood 2017","DOI":"10.1182\/blood.V130.Suppl_1.901.901"},{"key":"10.1002\/14651858.CD013487-BIB0048|cit48","unstructured":"Gay F Bringhen S Offidani M Liberati A Cellini C Magarotto V Efficacy and safety of 3 lenalidomide-based combinations in elderly newly diagnosed multiple myeloma patients: results from the phase 3 community based emn01 trial Haematologica 2013 95 6"},{"issue":"3","key":"10.1002\/14651858.CD013487-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/ajh.24621","article-title":"Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials","volume":"92","author":"Gentile","year":"2017","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD013487-BIB0050|cit50","unstructured":"Larocca A Bringhen S Petrucci MT Offidani M Benevolo G Galli M Early death in elderly patients with newly diagnosed multiple myeloma treated with new drugs: a pooled analysis of two randomized phase 3 trials Haematologica 2015 51 2"},{"key":"10.1002\/14651858.CD013487-BIB0051|cit51","unstructured":"Larocca A Bringhen S Petrucci MT Offidani M Paoli L Pietrantuono G Early mortality in elderly newly diagnosed multiple myeloma patients treated with novel agents: a pooled analysis of two large randomized phase III trials Haematologica 2015 81 2"},{"key":"10.1002\/14651858.CD013487-BIB0052|cit52","unstructured":"Larocca A Magarotto V Offidani M Pour L Liberati AM Benevolo G Lenalidomide-dexamethasone vs melphalan-prednisone-lenalidomide vs cyclophosphamide-prednisone-lenalidomide in ndmm Clinical Lymphoma, Myeloma and Leukemia 2013 S113 s114"},{"key":"10.1002\/14651858.CD013487-BIB0053|cit53","doi-asserted-by":"crossref","unstructured":"Larocca A Offidani M Ciccone G Guglielmelli T Cangialosi C Salvini M Impact of bortezomib-or lenalidomide-based induction treatment on high risk cytogenetic transplant-ineligible patients with newly diagnosed multiple myeloma enrolled in the gimema-MM-03-05 and EMN01 trials Blood 2017","DOI":"10.1182\/blood.V130.Suppl_1.744.744"},{"key":"10.1002\/14651858.CD013487-BIB0054|cit54","doi-asserted-by":"crossref","unstructured":"Magarotto V Bringhen S Hajek R Musto P Goldaniga MC Ledda A Lenalidomide-dexamethsone (RD) vs melphalan-lenalidomide-prednisone (MPR) vs cyclophosphamide-prednisone-lenalidomide (CPR) in elderly community-based newly diagnosed myeloma patients Haematologica 2014 103 4","DOI":"10.1016\/j.clml.2015.07.217"},{"key":"10.1002\/14651858.CD013487-BIB0055|cit55","unstructured":"Magarotto V Bringhen S Musto P Benevolo G Ledda A Genuardi M Feasibility of lenalidomide maintenance therapy in frail patients with multiple myeloma: subgroup analysis of a randomized phase 3 trial Haematologica 2015 100 1"},{"key":"10.1002\/14651858.CD013487-BIB0056|cit56","doi-asserted-by":"crossref","unstructured":"Magarotto V Bringhen S Musto P Benevolo G Ledda A Genuardi M Lenalidomide-dexamethasone or melphalan-lenalidomide-prednisone (MPR) or cyclophosphamide-prednisone-lenalidomide (CPR) for initial treatment of real life elderly patients with newly diagnosed multiple myeloma Clinical Lymphoma, Myeloma and Leukemia 2015 e69","DOI":"10.1016\/j.clml.2015.07.217"},{"issue":"9","key":"10.1002\/14651858.CD013487-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1182\/blood-2015-08-662627","article-title":"Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma","volume":"127","author":"Magarotto","year":"2016","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013487-BIB0058|cit58","unstructured":"Magarotto V Bringhen S Offidani M Benevolo G Patriarca F Palladino C Maintenance therapy with lenalidomide in elderly patients with newly diagnosed multiple myeloma: a Post-HOC analysis of the EMN01 trial Haematologica 2015 82"},{"key":"10.1002\/14651858.CD013487-BIB0059|cit59","unstructured":"Magarotto V Bringhen S Offidani M Liberati AM Benevolo G Patriarca F Lenalidomide plus dexamethasone (RD) vs melphalan-lenalidomide-prednisone (MPR) or cyclophosphamide-prednisone-lenalidomide (CPR) in elderly comunity-based newly diagnosed multiple myeloma patients: efficacy and safety results from a phase 3 trial Haematologica 2013 50"},{"key":"10.1002\/14651858.CD013487-BIB0060|cit60","doi-asserted-by":"crossref","unstructured":"Mateos MV Oriol A Mart\u00ednez-L\u00f3pez J Guti\u00e9rrez N Teruel AI L\u00f3pez de la Gu\u00eda A Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial Blood 2012 2581 8","DOI":"10.1182\/blood-2012-05-427815"},{"issue":"10","key":"10.1002\/14651858.CD013487-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","article-title":"Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial","volume":"11","author":"Mateos","year":"2010","journal-title":"Lancet Oncology"},{"issue":"12","key":"10.1002\/14651858.CD013487-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1182\/blood-2014-05-573733","article-title":"GEM2005 trial update comparing VMP\/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?","volume":"124","author":"Mateos","year":"2014","journal-title":"Blood"},{"issue":"10","key":"10.1002\/14651858.CD013487-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","article-title":"Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial","volume":"11","author":"Mateos","year":"2010","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD013487-BIB0064|cit64","unstructured":"Mateos MV Oriol A Martinez-Lopez J Teruel AI Lopez de la Guia A Blanchard MJ Do we still need the alkylators as part of the up front treatment of elderly newly diagnosed multiple myeloma patients? Updated follow-up of GEM2005MAS65 Spanish trial comparing VMP vs VTP as induction Haematologica 2014 221"},{"key":"10.1002\/14651858.CD013487-BIB0065|cit65","doi-asserted-by":"crossref","unstructured":"Mookerjee A Gupta R Jasrotia S Sahoo R Kumar R Thulkar S Bortezomib, lenalidomide and low-dose dexamethasone (VRD) versus lenalidomide and low-dose dexamethasone (LD) for newly-diagnosed multiple myeloma-a randomized phase III study Blood 2017","DOI":"10.1182\/blood.V130.Suppl_1.906.906"},{"issue":"5","key":"10.1002\/14651858.CD013487-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood-2011-02-338665","article-title":"Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation","volume":"118","author":"Morgan","year":"2011","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013487-BIB0067|cit67","unstructured":"Moon MA Triple therapy added toxicity without survival benefit in multiple myeloma Journal of Clinical Oncology 2015 11 7 3 4"},{"key":"10.1002\/14651858.CD013487-BIB0068|cit68","unstructured":"Niesvizky R Flinn I Rifkin R Charu V Essell J Gaffar Y Efficacy and safety of three bortezomib-based induction regimens followed by weekly bortezomib maintenance therapy in newly diagnosed multiple myeloma (MM) patients (PTS) ineligible for transplant: results of the phase 3B upfront study Haematologica 2011 S98"},{"key":"10.1002\/14651858.CD013487-BIB0069|cit69","doi-asserted-by":"crossref","unstructured":"Niesvizky R Flinn I Rifkin R Gabrail N Charu V Clowney B Patient-reported quality of life (QOL) in previously untreated, elderly multiple myeloma (MM) patients treated with bortezomib-based regimens: results from the phase 3B upfront study Haematologica 2011 123 4","DOI":"10.1182\/blood.V116.21.3026.3026"},{"issue":"33","key":"10.1002\/14651858.CD013487-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1200\/JCO.2014.58.7618","article-title":"Community-based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens","volume":"33","author":"Niesvizky","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013487-BIB0071|cit71","doi-asserted-by":"crossref","unstructured":"Niesvizky R Flinn IW Rifkin R Gabrail N Charu V Clowney B Patient-reported quality of life (QOL) in elderly, newly diagnosed multiple myeloma (MM) patients receiving bortezomib-based combinations: results from all randomized patients in the community-based, phase 3b UPFRONT study Blood 2011","DOI":"10.1182\/blood.V118.21.1864.1864"},{"key":"10.1002\/14651858.CD013487-BIB0072|cit72","doi-asserted-by":"crossref","unstructured":"Niesvizky R Flinn IW Rifkin RM Gabrail N Charu V Gaffar Y Impact of baseline characteristics on efficacy and safety after bortezomib-based induction and maintenance in newly diagnosed multiple myeloma (MM) patients ineligible for transplant in the phase IIIb UPFRONT study Journal of Clinical Oncology 2011","DOI":"10.1200\/jco.2011.29.15_suppl.8072"},{"key":"10.1002\/14651858.CD013487-BIB0073|cit73","doi-asserted-by":"crossref","unstructured":"Niesvizky R Flinn IW Rifkin RM Gabrail NY Charu V Clowney B Phase 3b UPFRONT study: safety and efficacy of weekly bortezomib maintenance therapy after bortezomib-based induction regimens in elderly, newly diagnosed multiple myeloma patients Blood 2010","DOI":"10.1182\/blood.V116.21.619.619"},{"key":"10.1002\/14651858.CD013487-BIB0074|cit74","doi-asserted-by":"crossref","unstructured":"Niesvizky R Reeves J Flinn I Gabrail N Rifkin R Charu V Phase 3b upfront study: interim results from a community based prospective randomized trial evaluating three bortezomib-based regimens in elderly, newly diagnosed multiple myeloma patients Haematologica 2010 144","DOI":"10.1182\/blood.V114.22.129.129"},{"key":"10.1002\/14651858.CD013487-BIB0075|cit75","doi-asserted-by":"crossref","unstructured":"Palumbo A Bringhen S Caravita T Callea V Zambello R Pregno P A prospective randomized controlled trial of oral melphalan, prednisone, thalidomide versus oral melphalan, prednisone in elderly newly diagnosed myeloma patients Haematologica 2006","DOI":"10.1002\/cncr.21342"},{"key":"10.1002\/14651858.CD013487-BIB0076|cit76","unstructured":"Palumbo A Bringhen S Caravita T Falcone A Callea V Cangialosi C Oral melphalan, prednisone, thalidomide versus oral melphalan, prednisone in elderly newly diagnosed myeloma patients Haematologica 2007 147"},{"issue":"9513","key":"10.1002\/14651858.CD013487-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013487-BIB0078|cit78","doi-asserted-by":"crossref","unstructured":"Palumbo A Bringhen S Liberati AM Caravita T Falcone A Callea V Oral melphalan, prednisone and thalidomide in elderly multiple myeloma patients: updated results of a randomized controlled trial Haematologica 2008 363 5","DOI":"10.1182\/blood-2008-04-149427"},{"key":"10.1002\/14651858.CD013487-BIB0079|cit79","doi-asserted-by":"crossref","unstructured":"Palumbo A Bringhen S Liberati AM Caravita T Falcone A Callea V Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial Blood 2008 3107 14","DOI":"10.1182\/blood-2008-04-149427"},{"key":"10.1002\/14651858.CD013487-BIB0080|cit80","unstructured":"Cavo M Dimopoulos M Palumbo A Weisel K Delforge M Blade J Impact of renal impairment on the efficacy and safety of melphalan-prednisone-lenalidomide (LEN) induction followed by LEN maintenance in newly diagnosed multiple myeloma: mM-015 post-hoc analysis Haematologica 2013 330 1"},{"issue":"5","key":"10.1002\/14651858.CD013487-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3324\/haematol.2012.074534","article-title":"Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial","volume":"98","author":"Dimopoulos","year":"2013","journal-title":"Haematologica"},{"issue":"7","key":"10.1002\/14651858.CD013487-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.3109\/10428194.2013.847933","article-title":"Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged? 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial","volume":"55","author":"Dimopoulos","year":"2014","journal-title":"Leukemia and Lymphoma"},{"key":"10.1002\/14651858.CD013487-BIB0083|cit83","unstructured":"Gay F Cavallo F Raimondo F Hardan I Nagler A Petrucci MT Impact of continuous treatment vs fixed duration of therapy in newly diagnosed myeloma patients: pFS1, PFS2, OS endpoints Haematologica 2014 519"},{"key":"10.1002\/14651858.CD013487-BIB0084|cit84","doi-asserted-by":"crossref","unstructured":"Palumbo A Adam Z Kropff M Foa R Catalano J Gisslinger H A phase 3 study evaluating the efficacy and safety of lenalidomide (len) combined with melphalan and prednisone followed by continuous lenalidomide maintenance (MPR-R) in patients (pts) = 65 Years (yrs) with newly diagnosed multiple myeloma (NDMM): updated results for pts aged 65-75 yrs enrolled in MM-015 Blood 2011","DOI":"10.1182\/blood.V118.21.475.475"},{"key":"10.1002\/14651858.CD013487-BIB0085|cit85","doi-asserted-by":"crossref","unstructured":"Palumbo A Delforge M Catalano J Hajek R Kropff M Petrucci MT A phase 3 study evaluating the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients 65 years with newly diagnosed multiple myeloma (NDMM): continuous use of lenalidomide vs fixed-duration regimens Blood 2010","DOI":"10.1182\/blood.V116.21.622.622"},{"key":"10.1002\/14651858.CD013487-BIB0086|cit86","doi-asserted-by":"crossref","unstructured":"Palumbo A Dimopoulos M Delforge M Hajek R Kropff M Petrucci M A phase 3 study to determine the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients = 65 years with newly diagnosed multiple myeloma (NDMM) Haematologica 2010 234 5","DOI":"10.1182\/blood.V116.21.622.622"},{"issue":"30","key":"10.1002\/14651858.CD013487-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1200\/JCO.2014.60.2466","article-title":"Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma","volume":"33","author":"Palumbo","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"19","key":"10.1002\/14651858.CD013487-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma.","volume":"366","author":"Palumbo","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013487-BIB0089|cit89","doi-asserted-by":"crossref","unstructured":"Palumbo A Kropff M Hajek R Delforge M Catalano J Petrucci MT Incidence of second primary malignancy (SPM) in melphalan-prednisone-lenalidomide combination followed by lenalidomide maintenance (MPR-R) in newly diagnosed multiple myeloma (MM) patients=65 years Haematologica 2011 218","DOI":"10.1200\/jco.2011.29.15_suppl.8007"},{"issue":"23","key":"10.1002\/14651858.CD013487-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","article-title":"Efficacy and safety of once-weekly bortezomib in multiple myeloma patients","volume":"116","author":"Bringhen","year":"2010","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013487-BIB0091|cit91","doi-asserted-by":"crossref","unstructured":"Bringhen S Larocca A Rossi D Romano A Genuardi M Ria R Efficacy and safety of once weekly bortezomib in multiple myeloma patients Blood 2010","DOI":"10.1182\/blood.V116.21.3029.3029"},{"key":"10.1002\/14651858.CD013487-BIB0092|cit92","unstructured":"Bringhen S Magarotto V Rossi D Ria R Offidani M Patriarca F Bortezomib, melphalan, prednisone and thalidomide followed by maintenance with bortezomib and thalidomide (VMPT-VT) vs bortezomib, melphalan, prednisone (VMP) alone as first line treatment of multiple myeloma: updated follow-up and impact of prognostic factors Haematologica 2011 67 8"},{"key":"10.1002\/14651858.CD013487-BIB0093|cit93","unstructured":"Corso A Raimondo F Mangiacavalli S Ria R Offidani M Pascutto C Bortezomib-based therapy overcomes the prognostic role of ISS score in multiple myeloma patients not eligible for transplant Haematologica 2011 128"},{"key":"10.1002\/14651858.CD013487-BIB0094|cit94","unstructured":"Gay F Cavallo F Raimondo F Hardan I Nagler A Petrucci MT Impact of continuous treatment vs fixed duration of therapy in newly diagnosed myeloma patients: pFS1, PFS2, OS endpoints Haematologica 2014 519"},{"key":"10.1002\/14651858.CD013487-BIB0095|cit95","unstructured":"Gay F Larocca A Petrucci MT Musto P Liberati AM Callea V Achievement of complete remission is a strong prognostic factor in 895 elderly myeloma patients treated with melphalan-prednisone based-regimens: results of 3 multicenter Italian trials Haematologica 2010 236"},{"issue":"3","key":"10.1002\/14651858.CD013487-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/ajh.24621","article-title":"Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials","volume":"92","author":"Gentile","year":"2017","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD013487-BIB0097|cit97","unstructured":"Genuardi M Bringhen S Rossi D Spadano A Pisani F Nozza A Evaluation of the efficacy and safety of weekly infusion bortezomib in elderly patients with newly diagnosed multiple myeloma Haematologica 2010 S104 s105"},{"key":"10.1002\/14651858.CD013487-BIB0098|cit98","unstructured":"Larocca A Bringhen S Petrucci MT Offidani M Paoli L Pietrantuono G Early mortality in elderly newly diagnosed multiple myeloma patients treated with novel agents: a pooled analysis of two large randomized phase III trials Haematologica 2015 81 2"},{"key":"10.1002\/14651858.CD013487-BIB0099|cit99","unstructured":"Larocca A Bringhen S Offidani M Benevolo G Galli M Early death in elderly patients with newly diagnosed multiple myeloma treated with new drugs: a pooled analysis of two randomized phase 3 trials Haematologica 2015 51 2"},{"key":"10.1002\/14651858.CD013487-BIB0100|cit100","doi-asserted-by":"crossref","unstructured":"Larocca A Offidani M Ciccone G Guglielmelli T Cangialosi C Salvini M Impact of bortezomib-or lenalidomide-based induction treatment on high risk cytogenetic transplant-ineligible patients with newly diagnosed multiple myeloma enrolled in the gimema-MM-03-05 and EMN01 trials Blood 2017","DOI":"10.1182\/blood.V130.Suppl_1.744.744"},{"issue":"22","key":"10.1002\/14651858.CD013487-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.1182\/blood-2011-05-353995","article-title":"Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment","volume":"118","author":"Morabito","year":"2011","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013487-BIB0102|cit102","unstructured":"Morabito F Gentile M Mazzone C Rossi D Ria R Offidani M VMPT (bortezomib, melphalan, prednisone and thalidomide) followed by maintenance with bortezomib-thalidomide (VT) is active and well tolerated in newly diagnosed patients with multiple myeloma (MM) with moderate renal impairment (RI) ineligible for autologous stem cell transplantation: results from a cohort analysis of a phase III randomized controlled trial Haematologica 2011 S98 s99"},{"key":"10.1002\/14651858.CD013487-BIB0103|cit103","doi-asserted-by":"crossref","unstructured":"Palumbo A Bringhen S Cavalli M Ria R Offidani M Patriarca F Bortezomib, melphalan, prednisone and thalidomide followed by maintenance with bortezomib and thalidomide (VMPT-VT) for initial treatment of elderly multiple myeloma patients: updated follow-up and impact of prognostic factors Blood 2010","DOI":"10.1182\/blood.V116.21.620.620"},{"issue":"7","key":"10.1002\/14651858.CD013487-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1200\/JCO.2013.52.0023","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival","volume":"32","author":"Palumbo","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013487-BIB0105|cit105","first-page":"S101","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by continuous bortezomib-thalidomide for initial therapy of elderly multiple myeloma patients: a prospective randomized trial","volume":"95","author":"Palumbo","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"34","key":"10.1002\/14651858.CD013487-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial","volume":"28","author":"Palumbo","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"34","key":"10.1002\/14651858.CD013487-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial","volume":"28","author":"Palumbo","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013487-BIB0108|cit108","doi-asserted-by":"crossref","unstructured":"Palumbo A Bringhen S Rossi D Cavalli M Ria R Gentilini S Overall survival benefit for bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in newly diagnosed multiple myeloma patients Blood 2012","DOI":"10.1182\/blood.V120.21.200.200"},{"key":"10.1002\/14651858.CD013487-BIB0109|cit109","unstructured":"Palumbo A Bringhen S Rossi D Cavalli M Ria R Offidani M A prospective randomized trial of bortezomib-melphalan-prednisone-thalidomide followed by continuous bortezomib-thalidomide for initial therapy of multiple myeloma: effect of age and co-morbidities Haematologica 2010 235 6"},{"key":"10.1002\/14651858.CD013487-BIB0110|cit110","doi-asserted-by":"crossref","unstructured":"Palumbo A Bringhen S Rossi D Magarotto V Raimondo F Ria R A prospective, randomized, phase iii study of bortezomib, melphalan, prednisone and thalidomide (VMPT) versus bortezomib, melphalan and prednisone (VMP) in elderly newly diagnosed myeloma patients Blood 2009 243","DOI":"10.1182\/blood.V112.11.652.652"},{"key":"10.1002\/14651858.CD013487-BIB0111|cit111","unstructured":"Palumbo A Bringhen S Rossi D Ria R Magarotto V Offidani M Bortezomib, melphalan, prednisone and thalidomide followed by bortezomib and thalidomide (VMPT-VT) as initial treatment of multiple myeloma (MM) patients older than 65 years: updated follow-up and prognostic factors Haematologica 2011 S80 s81"},{"key":"10.1002\/14651858.CD013487-BIB0112|cit112","unstructured":"Palumbo A Bringhen S Rossi D Ria R Magarotto V Offidani M Prognostic factors in elderly myeloma patients receiving bortezomib, melphalan, prednisone and thalidomide followed by bortezomib and thalidomide (VMPT-VT) as first line treatment Haematologica 2011 376"},{"issue":"30","key":"10.1002\/14651858.CD013487-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1200\/JCO.2014.60.2466","article-title":"Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma","volume":"33","author":"Palumbo","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013487-BIB0114|cit114","doi-asserted-by":"crossref","unstructured":"Palumbo AB Bringhen S Rossi D Berretta S Montefusco V Peccatori J A phase III study of VMPT versus VMP in newly diagnosed elderly myeloma patients Journal of Clinical Oncology 2009 437","DOI":"10.1200\/jco.2009.27.15_suppl.8515"},{"key":"10.1002\/14651858.CD013487-BIB0115|cit115","unstructured":"Brioli A Davies F Gregory W Hinsley S Marshall S Pawlyn C Low rate of secondary primary malignancies (SPMs) in newly diagnosed multiple myeloma (MM) patients treated with lenalidomide: first results from the MRC MM XI trial Haematologica 2013 104"},{"key":"10.1002\/14651858.CD013487-BIB0116|cit116","doi-asserted-by":"crossref","unstructured":"Jackson GH Davies FE Pawlyn C Cairns DA Striha A Collett C Lenalidomide is a highly effective maintenance therapy in myeloma patients of all ages; Results of the phase III myeloma XI study Blood 2016","DOI":"10.1182\/blood.V128.22.1143.1143"},{"key":"10.1002\/14651858.CD013487-BIB0117|cit117","unstructured":"Jones JR Cairns D Gregory W Sigsworth R Collett C Pawlyn C The NCRI Myeloma XI trial for newly diagnosed symptomatic multiple myeloma (NDMM); second primary malignancy (SPM) incidence when lenalidomide is used as an induction and maintenance treatment option British Journal of Haematology 2016 86"},{"issue":"12","key":"10.1002\/14651858.CD013487-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1038\/bcj.2016.114","article-title":"Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial","volume":"6","author":"Jones","year":"2016","journal-title":"Blood Cancer Journal"},{"key":"10.1002\/14651858.CD013487-BIB0119|cit119","doi-asserted-by":"crossref","unstructured":"Jones JR Cairns DA Sigsworth R Collett C Pawlyn C Striha A Myeloma XI trial for newly diagnosed multiple myeloma (NDMM); a report of second primary malignancy (SPM) rates and the importance of review of reported cases Blood 2015 1847","DOI":"10.1182\/blood.V126.23.1847.1847"},{"key":"10.1002\/14651858.CD013487-BIB0120|cit120","unstructured":"Pawlyn C Davies FE Cairns D Striha A Best P Sigsworth R Continuous treatment with lenalidomide improves outcomes in newly diagnosed myeloma patients not eligible for autologous stem cell transplant: results of the myeloma xi trial Blood 2017"},{"key":"10.1002\/14651858.CD013487-BIB0121|cit121","doi-asserted-by":"crossref","unstructured":"Pawlyn C Davies FE Gregory WM Szubert AJ Bell SE Ouzman J Sequential immunomodulatory drug (IMID) and proteosome inhibitor therapy improves response rates in newly diagnosed multiple myeloma: preliminary results from the myeloma XI trial Blood 2012","DOI":"10.1182\/blood.V120.21.335.335"},{"key":"10.1002\/14651858.CD013487-BIB0122|cit122","unstructured":"Pawlyn C Kaiser MF Cairns D Striha A Jones JR Shah V Factors predicting poor outcomes for myeloma patients at different ages: results from 3894 patients in the myeloma XI trial Blood 2017"},{"key":"10.1002\/14651858.CD013487-BIB0123|cit123","unstructured":"Tute RM Rawstron AC Cairns D Pawlyn C Davies F Collett C Minimal residual disease predicts outcome in transplant ineligible myeloma patients: results from the UK NCRI Myeloma XI trial British Journal of Haematology 2016 105"},{"key":"10.1002\/14651858.CD013487-BIB0124|cit124","unstructured":"Tute RM Rawstron AC Cairns DA Pawlyn C Davies FE Collett C Impact of minimal residual disease in transplant ineligible myeloma patients: results from the UK NCRI myeloma XI trial Blood 2016"},{"issue":"10","key":"10.1002\/14651858.CD013487-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.3109\/10428194.2011.584006","article-title":"A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant","volume":"52","author":"Sacchi","year":"2011","journal-title":"Leukemia and Lymphoma"},{"issue":"5","key":"10.1002\/14651858.CD013487-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1600-0609.2011.01599.x","article-title":"Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma","volume":"86","author":"Delforge","year":"2011","journal-title":"European Journal of Haematology"},{"issue":"1","key":"10.1002\/14651858.CD013487-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1600-0609.2010.01533.x","article-title":"Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study","volume":"86","author":"Dimopoulos","year":"2011","journal-title":"European Journal of Haematology"},{"issue":"36","key":"10.1002\/14651858.CD013487-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1200\/JCO.2009.22.2232","article-title":"VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study","volume":"27","author":"Dimopoulos","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"19","key":"10.1002\/14651858.CD013487-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1182\/blood-2010-03-275800","article-title":"Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone","volume":"116","author":"Harousseau","year":"2010","journal-title":"Blood"},{"issue":"13","key":"10.1002\/14651858.CD013487-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2009.26.0638","article-title":"Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial","volume":"28","author":"Mateos","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013487-BIB0131|cit131","unstructured":"Palumbo A Schlag R Khuageva N Dimopoulos M Kropff M Spicka I Prolonged therapy with bortezomib plus melphalan-prednisone (VMP) results in improved quality and duration of response in the phase III vista study in previously untreated multiple myeloma (MM) Haematologica 2008"},{"key":"10.1002\/14651858.CD013487-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1365-2141.2011.08569.x","article-title":"Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial","volume":"153","author":"Richardson","year":"2011","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD013487-BIB0133|cit133","doi-asserted-by":"crossref","unstructured":"San Miguel JF Schlag R Khuageva N Shpilberg O Dimopoulos M Kropff M MMY-3002: a phase 3 study comparing Bortezomib-Melphalan-Prednisone (VMP) with Melphalan-Prednisone (MP) in newly diagnosed multiple myeloma Blood 2007","DOI":"10.1182\/blood.V110.11.76.76"},{"issue":"9","key":"10.1002\/14651858.CD013487-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013487-BIB0135|cit135","doi-asserted-by":"crossref","unstructured":"San Miguel JF Schlag R Khuageva NK Dimopoulos MA Shpilberg O Kropff M Continued overall survival benefit after 5 years' follow-up with bortezomib-melphalan-prednisone (VMP) versus melphalan-prednisone (MP) in patients with previously untreated multiple myeloma, and no increased risk of second primary malignancies: final results of the phase 3 VISTA trial Blood 2011","DOI":"10.1182\/blood.V118.21.476.476"},{"key":"10.1002\/14651858.CD013487-BIB0136|cit136","unstructured":"San Miguel JF Schlag R Khuageva NK Dimopoulos MA Shpilberg O Kropff M Superior efficacy with bortezomib plus melphalan-prednisone (VMP) versus melphalan-prednisone (MP) alone in previously untreated multiple myeloma (MM): results of the phase III MMY-3002 VISTA study Haematologica 2008"},{"key":"10.1002\/14651858.CD013487-BIB0137|cit137","doi-asserted-by":"crossref","unstructured":"San Miguel JF Schlag R Khuageva NK Dimopoulos MA Shpilberg O Kropff M Updated follow-up and results of subsequent therapy in the phase III vista trial: bortezomib plus melphalan-prednisone versus melphalan-prednisone in newly diagnosed multiple myeloma Blood 2009 242","DOI":"10.1182\/blood.V112.11.650.650"},{"issue":"9","key":"10.1002\/14651858.CD013487-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2217\/imt.11.104","article-title":"An overview of the VISTA trial: newly diagnosed, untreated patients with multiple myeloma ineligible for stem cell transplantation","volume":"3","author":"Spicka","year":"2011","journal-title":"Immunotherapy"},{"key":"10.1002\/14651858.CD013487-BIB0139|cit139","doi-asserted-by":"crossref","unstructured":"Stewart AK Jacobus S Fonseca R Weiss M Callander NS Chanan Khan AA E1A06: a phase III trial comparing melphalan, prednisone, and thalidomide (MPT) versus melphalan, prednisone, and lenalidomide (MPR) in newly diagnosed multiple myeloma MM) Haematologica 2014 220","DOI":"10.1200\/jco.2014.32.15_suppl.8511"},{"issue":"11","key":"10.1002\/14651858.CD013487-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1182\/blood-2014-12-613927","article-title":"Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma","volume":"126","author":"Stewart","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1002\/14651858.CD013487-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1182\/blood-2009-08-237974","article-title":"Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma","volume":"116","author":"Waage","year":"2010","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013487-BIB0142|cit142","doi-asserted-by":"crossref","unstructured":"Waage A Gimsing P Juliusson G Turesson I Fayers P Melphalan-prednisone-thalidomide to newly diagnosed patients with multiple myeloma: a placebo controlled randomised phase 3 trial Blood 2007 32a","DOI":"10.1182\/blood.V110.11.78.78"},{"key":"10.1002\/14651858.CD013487-BIB0143|cit143","unstructured":"Beurden-Tan C Blommestein H Zweegman S Sonneveld P The relationship of response on time to next treatment based on evidence from two RCTs in newly diagnosed stem cell transplantation ineligible multiple myeloma patients Blood 2016"},{"key":"10.1002\/14651858.CD013487-BIB0144|cit144","doi-asserted-by":"crossref","unstructured":"Verelst S Termorshuizen F Uyl-De Groot C Sonneveld P Wijermans P Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQOL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial (HOVON 49) Haematologica 2011 S135","DOI":"10.1007\/s00277-011-1224-1"},{"key":"10.1002\/14651858.CD013487-BIB0145|cit145","doi-asserted-by":"crossref","unstructured":"Verelst S Termorshuizen F Uyl-de Groot C Schaafsma MR Ammerlaan R Wittebol S Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQOL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial Blood 2010","DOI":"10.1182\/blood.V116.21.2972.2972"},{"issue":"12","key":"10.1002\/14651858.CD013487-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1007\/s00277-011-1224-1","article-title":"Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial","volume":"90","author":"Verelst","year":"2011","journal-title":"Annals of Hematology"},{"key":"10.1002\/14651858.CD013487-BIB0147|cit147","doi-asserted-by":"crossref","unstructured":"Wijermans P Schaafsma M Norden Y Ammerlaan R Sonneveld P Wittebol S Melphalan + prednisone vs melphalan + prednisone + thalidomide in induction therapy for multiple myeloma in elderly patients: first interim results of the Dutch cooperative group HOVON Haematologica 2008 177","DOI":"10.1182\/blood.V112.11.649.649"},{"issue":"11","key":"10.1002\/14651858.CD013487-BIB0148|cit148","first-page":"241","article-title":"Melphalan + prednisone versus melphalan + prednisone + thalidomide in induction therapy for multiple myeloma in elderly patients: final analysis of the Dutch Cooperative Group HOVON 49 study","volume":"112","author":"Wijermans","year":"2009","journal-title":"Blood"},{"issue":"19","key":"10.1002\/14651858.CD013487-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1200\/JCO.2009.26.1610","article-title":"Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study","volume":"28","author":"Wijermans","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013487-BIB0150|cit150","unstructured":"Beurden-Tan C Blommestein H Zweegman S Sonneveld P The relationship of response on time to next treatment based on evidence from two RCTs in newly diagnosed stem cell transplantation ineligible multiple myeloma patients Blood 2016"},{"key":"10.1002\/14651858.CD013487-BIB0151|cit151","unstructured":"Kongsgaard Nielsen L Stege C Witte B Holt B Mellqvist UH Salomo M Health-related quality of life in non-transplant eligible newly diagnosed multiple myeloma patients treated with melphalan\/prednisolone plus either thalidomide or lenalidomide; results of the HOVON87\/NMSG18 study Quality of Life Research 2017 56 7"},{"key":"10.1002\/14651858.CD013487-BIB0152|cit152","unstructured":"Stege C Holt B Mellqvist UH Levin MD Salomo M Abildgaard N Frailty predicts survival and toxicity in newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation; report of the HOVON-87\/NMSG-18 study group Blood 2017"},{"key":"10.1002\/14651858.CD013487-BIB0153|cit153","unstructured":"Stege C Kongsgaard Nielsen L Witte B Holt B Mellqvist UH Salomo M Quality of life with melphalan\/prednisone plus either thalidomide (MPT-T) or lenalidomide (MPR-R) in non-transplant eligible newly diagnosed multiple myeloma; Results of the Hovon87\/NMSG18 study Haematologica 2017 190"},{"issue":"9","key":"10.1002\/14651858.CD013487-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood-2015-11-679415","article-title":"Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma","volume":"127","author":"Zweegman","year":"2016","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013487-BIB0155|cit155","unstructured":"A multicenter parallel-group, placebo controlled, randomized, double-blind study of combination thalidomide plus glucocorticoid therapy versus glucocorticoid therapy alone as induction therapy for previously untreated subjects with multiple myeloma available at: https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-00500364\/full"},{"key":"10.1002\/14651858.CD013487-BIB0156|cit156","unstructured":"Study of bortezomib and Revlimid \u2122 for patients relapsing or progressing on total therapy II available at: https:\/\/clinicaltrials.gov\/show\/nct00093028"},{"key":"10.1002\/14651858.CD013487-BIB0157|cit157","doi-asserted-by":"crossref","unstructured":"Barlogie B Rasmussen E Tricot G Crowley J Management of patients with multiple myeloma (MM) failing total therapy 2 (TT 2) according to thalidomide (THAL) randomization Blood 2004 414a","DOI":"10.1182\/blood.V104.11.1483.1483"},{"key":"10.1002\/14651858.CD013487-BIB0158|cit158","unstructured":"Brioli A Galli M Tacchetti P Crippa C Spadano T Pezzi A A combination therapy with bortezomib (BOR) and thalidomide in newly diagnosed myeloma patients is associated with a low incidence of second primary malignancies (SPMS) Haematologica 2014 373"},{"key":"10.1002\/14651858.CD013487-BIB0159|cit159","unstructured":"Facon T Mary JY Attal M Pegourie B Harousseau JL Sadoun A Melphalan-prednisone versus dexamethasone-based regimens for newly diagnosed myeloma patients aged 65-75 years. Final analysis of the IFM 95-01 trial on 489 patients Blood 2003 147a"},{"key":"10.1002\/14651858.CD013487-BIB0160|cit160","doi-asserted-by":"crossref","unstructured":"Facon T Mary JY P\u00e9gourie B Attal M Renaud M Sadoun A Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy Blood 2006 107 4 1292 8","DOI":"10.1182\/blood-2005-04-1588"},{"key":"10.1002\/14651858.CD013487-BIB0161|cit161","unstructured":"Phase 3 study of carfilzomib, melphalan, prednisone vs bortezomib, melphalan, prednisone in newly diagnosed multiple myeloma available at: ttps:\/\/clinicaltrials.gov\/show\/nct01818752"},{"issue":"1","key":"10.1002\/14651858.CD013487-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1016\/j.clml.2017.03.045","article-title":"Phase 3 Study (CLARION) of carfilzomib, melphalan, prednisone (KMP) v bortezomib, melphalan, prednisone (VMP) in newly diagnosed multiple myeloma (NDMM)","volume":"17","author":"Facon","year":"2017","journal-title":"Clinical Lymphoma, Myeloma and Leukemia"},{"key":"10.1002\/14651858.CD013487-BIB0163|cit163","doi-asserted-by":"crossref","unstructured":"Facon T Kumar SK Plesner T Orlowski RZ Moreau P Bahlis N LBA-2 phase 3 randomized study of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in patients with newly diagnosed multiple myeloma (NDMM) ineligible for transplant (MAIA) Blood 2018 LBA 2","DOI":"10.1182\/blood-2018-120737"},{"key":"10.1002\/14651858.CD013487-BIB0164|cit164","doi-asserted-by":"crossref","unstructured":"Foa R Weber D Dimopoulos M Olesnyckyj M Yu Z Zeldis J Lenalidomide\/dexamethasone improves response and prolongs time to progression, even in patients with IgA multiple myeloma: a sub-analysis of the MM-009\/010 studies Blood 2007 284b","DOI":"10.1182\/blood.V110.11.4839.4839"},{"key":"10.1002\/14651858.CD013487-BIB0165|cit165","unstructured":"Harousseau JL Attal M The IFM-90 trial Hematology Journal 2003 S55"},{"key":"10.1002\/14651858.CD013487-BIB0166|cit166","unstructured":"Hejlova N Hajek R Adam Z Scudla Z Bacovsky J Koza V Report of the \"4W\" trial of the Czech myeloma group Hematology Journal 2000 168 9"},{"issue":"2","key":"10.1002\/14651858.CD013487-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2141.2004.05186.x","article-title":"Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma","volume":"127","author":"Hern\u00e1ndez","year":"2004","journal-title":"British Journal of Heamatology"},{"issue":"19","key":"10.1002\/14651858.CD013487-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","article-title":"Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013487-BIB0169|cit169","unstructured":"Patients with newly diagnosed multiple myeloma comparing KTd vs. KRd induction therapy and investigating a K-mono maintenance strategy Available at: https:\/\/clinicaltrials.gov\/show\/nct02891811"},{"key":"10.1002\/14651858.CD013487-BIB0170|cit170","unstructured":"Ludwig H AGMT-MM2 A randomized phase II study in transplant ineligible patients with newly diagnosed multiple myeloma (NDMM) comparing Carfilzomib + Thalidomide + Dexamethasone(KTd) with Carfilzomib + Lenalidomide + Dexamethasone (KRd) induction therapy followed by Carfilzomib (K) maintenance or control Magazine of European Medical Oncology 2017 S44 s45"},{"key":"10.1002\/14651858.CD013487-BIB0171|cit171","doi-asserted-by":"crossref","unstructured":"Mateos MV Gutierrez NC Martin ML Martinez-Lopez J Hernandez MT Martinez R Bortezomib plus melphalan and prednisone (VMP) followed by lenalidomide and dexamethasone (RD) in newly diagnosed elderly myeloma patients overcome the poor prognosis of high-risk cytogenetic abnormalities (CA) detected by fluorescence in situ hibridization (FISH) Blood 2015 4243","DOI":"10.1182\/blood.V126.23.4243.4243"},{"issue":"4","key":"10.1002\/14651858.CD013487-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1182\/blood-2015-08-666537","article-title":"Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM","volume":"127","author":"Mateos","year":"2016","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013487-BIB0173|cit173","unstructured":"Mateos MV Martinez-Lopez J Hernandez M Martinez R Rosinol L Ocio EM Depth of response as surrogate marker for progression-free survival and overall survival in elderly newly diagnosed myeloma patients treated with VMP and Rd: gEM2010MAS65 Haematologica 2017 143"},{"key":"10.1002\/14651858.CD013487-BIB0174|cit174","doi-asserted-by":"crossref","unstructured":"Mateos MV Martinez-Lopez J Hernandez MT Ocio EM Rosinol L Martinez R Bortezomib, melphalan, prednisone (VMP) and lenalidomide plus dexamethasone (RD) is the optimal combination for patients with newly diagnosed multiple myeloma (MM) patients between 65 and 80 years Blood 2015 1848","DOI":"10.1182\/blood.V126.23.1848.1848"},{"key":"10.1002\/14651858.CD013487-BIB0175|cit175","doi-asserted-by":"crossref","unstructured":"Facon T Cavo M Jakubowiak A San Miguel J Kumar S Orlowski RZ Two randomized open-label studies of daratumumab (DARA) plus standard of care treatment versus standard of care alone in patients with previously untreated multiple myeloma (MM) ineligible for high-dose therapy: 54767414MMY3007 (Alcyone) and 54767414MMY3008 (Maia) Clinical Lymphoma, Myeloma and Leukemia 2015 e294 5","DOI":"10.1016\/j.clml.2015.07.600"},{"key":"10.1002\/14651858.CD013487-BIB0176|cit176","doi-asserted-by":"crossref","unstructured":"Mateos MV Cavo M Jakubowiak AJ Carson RL Qi M Bandekar R A randomized open-label study of bortezomib, melphalan, and prednisone (VMP) versus daratumumab (DARA) plus VMP in patients with previously untreated multiple myeloma (MM) who are ineligible for high-dose therapy: 54767414MMY3007 (Alcyone) Journal of Clinical Oncology 2015 supplement 1 (no pagination)","DOI":"10.1200\/jco.2015.33.15_suppl.tps8608"},{"key":"10.1002\/14651858.CD013487-BIB0177|cit177","doi-asserted-by":"crossref","unstructured":"Mateos MV Dimopoulos MA Cavo M Suzuki K Jakubowiak A Knop S Daratumumab plus bortezomib, melphalan, and prednisone (D-VMP) versus bortezomib, melphalan, and prednisone (VMP) in newly diagnosed multiple myeloma (NDMM) patients (PTS) ineligible for transplant: a phase 3 ran-domized study (alcyone) Haematologica 2018 22","DOI":"10.1182\/blood.V130.Suppl_1.LBA-4.LBA-4"},{"issue":"6","key":"10.1002\/14651858.CD013487-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013487-BIB0179|cit179","doi-asserted-by":"crossref","unstructured":"Mateos MV Dimopoulos MA Cavo M Suzuki K Jakubowiak AJ Knop S Phase 3 randomized study of daratumumab plus bortezomib, melphalan, and prednisone (D-VMP) versus bortezomib, melphalan, and prednisone (VMP) in newly diagnosed multiple myeloma (NDMM) patients (Pts) ineligible for transplant (ALCYONE) Blood 2017 Supplement 1 (no pagination)","DOI":"10.1182\/blood.V130.Suppl_1.LBA-4.LBA-4"},{"key":"10.1002\/14651858.CD013487-BIB0180|cit180","doi-asserted-by":"crossref","unstructured":"Stirrups R Daratumumab for untreated multiple myeloma Lancet Oncology 2018 19 2 e80","DOI":"10.1016\/S1470-2045(17)30951-8"},{"key":"10.1002\/14651858.CD013487-BIB0181|cit181","doi-asserted-by":"crossref","unstructured":"Merz M Salwender HJ Haenel M Bertsch U Kunz C Hielscher T Clinical risk factors for peripheral neuropathy in patients treated with subcutaneous or intravenous bortezomib for newly diagnosed multiple myeloma BLood 2015 4233","DOI":"10.1182\/blood.V126.23.4233.4233"},{"key":"10.1002\/14651858.CD013487-BIB0182|cit182","unstructured":"Montefusco V First-line treatment in elderly patients European journal of cancer 2013 S19"},{"key":"10.1002\/14651858.CD013487-BIB0183|cit183","unstructured":"Morgan G Davies FE Hawkins K Brown J Drayson MT The MRC Myeloma VII Trial of standard versus intensive treatment in patients <65 years of age with multiple myeloma Blood 2002 178a"},{"key":"10.1002\/14651858.CD013487-BIB0184|cit184","unstructured":"Bortezomib and dexamethasone with or without lenalidomide in treating patients with multiple myeloma previously treated with dexamethasone available at: https:\/\/clinicaltrials.gov\/show\/nct00522392"},{"key":"10.1002\/14651858.CD013487-BIB0185|cit185","unstructured":"UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A phase III trial for low risk myeloma available at: https:\/\/clinicaltrials.gov\/show\/nct00734877"},{"key":"10.1002\/14651858.CD013487-BIB0186|cit186","unstructured":"IXAZOMIB plus lenalidomide and dexamethasone versus placebo plus lenalidomide and dexamethasone in adult patients with newly diagnosed multiple myeloma available at: https:\/\/clinicaltrials.gov\/show\/nct01850524"},{"key":"10.1002\/14651858.CD013487-BIB0187|cit187","unstructured":"Bortezomib or carfilzomib With lenalidomide and dexamethasone in treating patients with newly diagnosed multiple myeloma available at: https:\/\/clinicaltrials.gov\/show\/nct01863550"},{"key":"10.1002\/14651858.CD013487-BIB0188|cit188","unstructured":"Study that compares 3 arm: MLN9708 dexamethasone, MLN9708 cyclophosphamide and dexamethasone, MLN9708 thalidomide and dexamethasone followed by maintenance with MLN9708 in newly diagnosed elderly multiple myeloma patients available at: https:\/\/clinicaltrials.gov\/show\/nct02586038"},{"key":"10.1002\/14651858.CD013487-BIB0189|cit189","unstructured":"A study comparing daratumumab, VELCADE (bortezomib), lenalidomide, and dexamethasone (D-VRd) with VELCADE, lenalidomide, and dexamethasone (VRd) in participants with untreated multiple myeloma and for whom hematopoietic stem cell transplant is not planned as initial therapy available at: https:\/\/clinicaltrials.gov\/show\/nct03652064"},{"key":"10.1002\/14651858.CD013487-BIB0190|cit190","unstructured":"Daratumumab, VELCADE (bortezomib), lenalidomide and dexamethasone compared to VELCADE, lenalidomide and dexamethasone in subjects with previously untreated multiple myeloma available at: https:\/\/clinicaltrials.gov\/show\/nct03710603"},{"key":"10.1002\/14651858.CD013487-BIB0191|cit191","unstructured":"Niesvizky R Pekle K Lyons L Pearse RN Bergsagel PL Schuster MW Dexamethsone alone, or in combination with low-dose thalidomide as induction therapy for advanced multiple myeloma, and the effect of the addition of clarithromycin (Biaxin?) on response rate. Interim results of a prospective, sequential, randomized trial Blood 2003 237a"},{"issue":"4","key":"10.1002\/14651858.CD013487-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/sj.thj.6200401","article-title":"Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma","volume":"5","author":"Offidani","year":"2004","journal-title":"Hematology Journal"},{"key":"10.1002\/14651858.CD013487-BIB0193|cit193","doi-asserted-by":"crossref","unstructured":"Lonial S Ribeiro De Oliveira M Yimer H Mateos MV Rifkin R Schjesvold F KEYNOTE-185: a randomized, open-label phase 3 study of pembrolizumab in combination with lenalidomide and lowdose dexamethasone in newly diagnosed and treatmentnaive multiple myeloma (MM) Annals of Oncology 2016 viii16","DOI":"10.1093\/annonc\/mdw525.51"},{"key":"10.1002\/14651858.CD013487-BIB0194|cit194","doi-asserted-by":"crossref","unstructured":"Palumbo A Mateos MV San Miguel J Shah J Thompson S Marinello P Pembrolizumab in combination with lenalidomide and low-dose dexamethasone in newly diagnosed and treatment-naive multiple myeloma (MM): randomized, phase 3 KEYNOTE-185 study Annals of Oncology 2016","DOI":"10.1093\/annonc\/mdw375.35"},{"key":"10.1002\/14651858.CD013487-BIB0195|cit195","doi-asserted-by":"crossref","unstructured":"Shah J Lonial S Oliveira MR Yimer H Mateos MV Rifkin R KEYNOTE-185: randomized, open-label, phase III study of pembrolizumab in combination with lenalidomide and low-dose dexamethasone in patients with newly diagnosed and treatment-naive multiple myeloma (MM) Journal for Immunotherapy of Cancer 2016","DOI":"10.1093\/annonc\/mdw525.51"},{"issue":"3","key":"10.1002\/14651858.CD013487-BIB0196|cit196","first-page":"188","article-title":"Eastern Cooperative Oncology Group E1A00: phase III randomized study of dexamethasone with or without thalidomide in patients with newly diagnosed multiple myeloma","volume":"1","author":"Greipp","year":"2003","journal-title":"Clinical Advances in Hematology & Ooncology"},{"issue":"3","key":"10.1002\/14651858.CD013487-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013487-BIB0198|cit198","doi-asserted-by":"crossref","unstructured":"Rajkumar SV Vesole DH Shepard PR Greipp PR A randomised phase III trial of thalidomide plus dexamethasone versus dexamethasone in newly diagnosed multiple myeloma (E1A00): a trial coordinated by the Eastern Cooperative Oncology Group Journal of Clinical Oncology 2004 558","DOI":"10.1200\/jco.2004.22.90140.6508"},{"key":"10.1002\/14651858.CD013487-BIB0199|cit199","doi-asserted-by":"crossref","unstructured":"Rajkumar SV Vesole DH Shepard R Greipp PR Thalidomide plus dexamethasone versus dexamethasone alone in newly diagnosed multiplemMyeloma (E1A00): results of a phase III trial coordinated by the Eastern Cooperative Oncology Group Blood 2004 63","DOI":"10.1182\/blood.V104.11.205.205"},{"key":"10.1002\/14651858.CD013487-BIB0200|cit200","doi-asserted-by":"crossref","unstructured":"Rajkumar SV Hussein M Catalano J Jedrzejcak W Sirkovich S Olesnyckyj M A multicenter, randomized, double-blind, placebo-controlled trial of thalidomide plus dexamethasone versus dexamethasone alone as initial therapy for newly diagnosed multiple myeloma Journal of Clinical Oncology 2006 426","DOI":"10.1200\/jco.2006.24.18_suppl.7517"},{"key":"10.1002\/14651858.CD013487-BIB0201|cit201","doi-asserted-by":"crossref","unstructured":"Rajkumar SV Hussein M Catalano J Jedrzejczak W Sirkovich S Olesnyckyj M A randomized, double-blind, placebo-controlled trial of thalidomide plus dexamethasone versus dexamethasone alone as primary therapy for newly diagnosed multiple myeloma Blood 2006 238","DOI":"10.1182\/blood.V108.11.795.795"},{"issue":"13","key":"10.1002\/14651858.CD013487-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2007.14.1853","article-title":"Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma","volume":"26","author":"Rajkumar","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013487-BIB0203|cit203","unstructured":"San Miguel J Blade J Samoilova O Shpilberg O Grosicki S Maloisel F Randomized, open-label, phase 2 study of siltuximab (an anti-il-6 mab) and bortezomib-melphalan-prednisone versus bortezomib-melphalan-prednisone in patients with previously untreated multiple myeloma Haematologica 2013 97"},{"issue":"26","key":"10.1002\/14651858.CD013487-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1182\/blood-2013-12-546374","article-title":"Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma","volume":"123","author":"San Miguel","year":"2014","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013487-BIB0205|cit205","unstructured":"PH III study of lenalidomide and dexamethasone with or without elotuzumab to treat peviously untreated multiple myeloma (ELO 1 substudy) available at: https:\/\/clinicaltrials.gov\/show\/nct01891643"},{"key":"10.1002\/14651858.CD013487-BIB0206|cit206","unstructured":"Phase III study of lenalidomide and dexamethasone with or without elotuzumab to treat newly diagnosed, previously untreated multiple myeloma available at: https:\/\/clinicaltrials.gov\/show\/nct01335399"},{"key":"10.1002\/14651858.CD013487-BIB0207|cit207","unstructured":"Takezako N Ohta K Handa H Hori M Kinoshita G Shelat S Elotuzumab plus lenalidomide\/dexamethasone (ELD) vs LD in patients with newly diagnosed multiple myeloma: phase 2, randomized, open-label study in Japan Blood 2017 supplement 1 (no pagination)"},{"key":"10.1002\/14651858.CD013487-BIB0208|cit208","unstructured":"S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma available at: https:\/\/clinicaltrials.gov\/show\/nct01668719"},{"key":"10.1002\/14651858.CD013487-BIB0209|cit209","doi-asserted-by":"crossref","unstructured":"Usmani SZ Hoering A Sexton R Ailawadhi S Shah JJ Fredette S SWOG 1211: a randomized phase I\/II study of optimal induction therapy for newly diagnosed high-risk multiple myeloma (HRMM) Journal of Clinical Oncology 2014 15 suppl.1 (no pagination)","DOI":"10.1200\/jco.2014.32.15_suppl.tps8624"},{"key":"10.1002\/14651858.CD013487-BIB0210|cit210","doi-asserted-by":"crossref","unstructured":"White DJ Kovacs MJ Belch A Stewart K Chen C Rubin S Phase II testing of lenalidomide plus melphalan for previously untreated older patients with multiple myeloma: toxicity data from the NCIC CTG MY.11 trial Blood 2007 63a","DOI":"10.1182\/blood.V110.11.189.189"},{"issue":"2","key":"10.1002\/14651858.CD013487-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3747\/co.2007.107","article-title":"Addition of lenalidomide to melphalan in the treatment of newly diagnosed multiple myeloma: the National Cancer Institute of Canada Clinical Trials Group MY.11 trial","volume":"14","author":"White","year":"2007","journal-title":"Current Oncology"},{"issue":"26","key":"10.1002\/14651858.CD013487-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"5838","DOI":"10.1182\/blood-2010-08-303487","article-title":"Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)","volume":"116","author":"Zonder","year":"2010","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013487-BIB0213|cit213","doi-asserted-by":"crossref","unstructured":"Zonder JA Crowley J Hussein MA Bolejack V Moore DF Whittenberger BF Superiority of lenalidomide (Len) plus high-dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): results of the randomized, double-blinded, placebo-controlled SWOG trial S0232 Blood 2007 32a","DOI":"10.1182\/blood.V110.11.77.77"},{"key":"10.1002\/14651858.CD013487-BIB0214|cit214","doi-asserted-by":"crossref","unstructured":"Zonder JA Crowley JJ Bolejack V Hussein MA Moore DF Whittenberger BF A randomized Southwest Oncology Group study comparing dexamethasone (D) to lenalidomide + dexamethasone (LD) as treatment of newly-diagnosed multiple myeloma (NDMM): impact of cytogenetic abnormalities on efficacy of LD, and updated overall study results Journal of Clinical Oncology 2008 459","DOI":"10.1200\/jco.2008.26.15_suppl.8521"},{"key":"10.1002\/14651858.CD013487-BIB0215|cit215","unstructured":"Zonder JA Phase III randomized study of dexamethasone with or without CC-5013 in patients with newly diagnosed multiple myeloma http:\/\/cochranelibrary-wiley.com\/o\/cochrane\/clcentral\/articles\/578\/CN-00501578\/frame.html 2003"},{"issue":"7","key":"10.1002\/14651858.CD013487-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41408-018-0102-7","article-title":"Disease and outcome disparities in multiple myeloma: exploring the role of race\/ethnicity in the Cooperative Group clinical trials","volume":"8","author":"Ailawadhi","year":"2018","journal-title":"Blood Cancer Journal"},{"key":"10.1002\/14651858.CD013487-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev-pathol-011110-130249","article-title":"Pathogenesis of myeloma","volume":"6","author":"Anderson","year":"2011","journal-title":"Annual Review of Pathology"},{"issue":"11","key":"10.1002\/14651858.CD013487-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.6004\/jnccn.2015.0167","article-title":"Multiple Myeloma, version 2.2016: Clinical Practice Guidelines in Oncology","volume":"13","author":"Anderson","year":"2015","journal-title":"Journal of the National Comprehensive Cancer Network"},{"issue":"5","key":"10.1002\/14651858.CD013487-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1182\/blood-2008-04-149385","article-title":"Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature","volume":"112","author":"Argyriou","year":"2008","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013487-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.pharmthera.2019.06.004","article-title":"Molecular mechanisms of cereblon-based drugs","volume":"202","author":"Asatsuma-Okumura","year":"2019","journal-title":"Pharmacology and Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD013487-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1182\/blood-2015-03-575365","article-title":"Promising therapies in multiple myeloma","volume":"126","author":"Bianchi","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD013487-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.3324\/haematol.2018.206912","article-title":"Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation - A Network Meta-analysis","volume":"104","author":"Blommestein","year":"2019","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD013487-BIB0223|cit223","unstructured":"Cancer Research UK Myeloma statistics https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/myeloma"},{"key":"10.1002\/14651858.CD013487-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jclinepi.2016.11.015","article-title":"Additional considerations are required when preparing a protocol for a systematic review with multiple interventions","volume":"83","author":"Chaimani","year":"2017","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD013487-BIB0225|cit225","unstructured":"Veritas Health Innovation Covidence systematic review software"},{"issue":"9","key":"10.1002\/14651858.CD013487-BIB0226|cit226","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncology"},{"key":"10.1002\/14651858.CD013487-BIB0227|cit227","unstructured":"Deeks JJ Higgins JPT Altman DG Chapter 9: Analysing data and undertaking meta-analyses on behalf of the Cochrane Statistical Methods Group. In: Higgins JP Green S (editors). Cochrane Handbook of Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"7-8","key":"10.1002\/14651858.CD013487-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis.","volume":"29","author":"Dias","year":"2010","journal-title":"Statistics in Medicine"},{"issue":"7109","key":"10.1002\/14651858.CD013487-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"5","key":"10.1002\/14651858.CD013487-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1182\/blood-2011-03-341669","article-title":"Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials","volume":"118","author":"Fayers P","year":"2011","journal-title":"Blood"},{"issue":"21","key":"10.1002\/14651858.CD013487-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2015-07-567958","article-title":"The novel mechanism of lenalidomide activity","volume":"126","author":"Fink","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD013487-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","article-title":"The proteasome and proteasome inhibitors in multiple myeloma","volume":"36","author":"Gandolfi","year":"2017","journal-title":"Cancer and Metastasis Reviews"},{"key":"10.1002\/14651858.CD013487-BIB0233|cit233","unstructured":"Higgins JP Chapter 7: Selecting studies and collecting data. In: Higgins JP Green S (editors). Cochrane Handbook of Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD013487-BIB0234|cit234","unstructured":"Higgins JP Altman DG Chapter 8: Assessing risk of bias in included studies. In: Higgins JP Green S (editors). Cochrane Handbook of Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org."},{"key":"10.1002\/14651858.CD013487-BIB0235|cit235","unstructured":"Higgins JP Deeks JJ Chapter 16: Special topics in statistics. In: Higgins JP Green S (editors). Cochrane Handbook of Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"5","key":"10.1002\/14651858.CD013487-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40265-017-0689-1","article-title":"Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience","volume":"77","author":"Holstein","year":"2017","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD013487-BIB0237|cit237","unstructured":"IMS Institute for Healthcare Informatics Understanding the Role and Use of Essential Medicines Lists, Available at: http:\/\/apps.who.int\/medicinedocs\/documents\/s21980en\/s21980en.pdf (accessed 30 August 2019) 2015"},{"key":"10.1002\/14651858.CD013487-BIB0238|cit238","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01461","article-title":"Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update","volume":"[Epub ahead of","author":"Key","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"22","key":"10.1002\/14651858.CD013487-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1182\/blood.V128.22.2624.2624","article-title":"Incidence and risk factors of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory agents","volume":"128","author":"Kimpton","year":"2016","journal-title":"Blood"},{"issue":"15","key":"10.1002\/14651858.CD013487-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1182\/blood-2017-04-778225","article-title":"Racial and ethnic disparities in hematologic malignancies","volume":"130","author":"Kirtane","year":"2017","journal-title":"Blood"},{"issue":"10","key":"10.1002\/14651858.CD013487-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1172\/JCI61188","article-title":"Molecular pathogenesis of multiple myeloma and its premalignant precursor","volume":"122","author":"Kuehl","year":"2012","journal-title":"Journal of Clinical Investigation"},{"issue":"3","key":"10.1002\/14651858.CD013487-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00228-015-1998-5","article-title":"First-line therapy for non-transplant eligible patients with multiple myeloma: direct and adjusted indirect comparison of treatment regimens on the existing market in Germany","volume":"72","author":"Kuhr","year":"2016","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD013487-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"11","DOI":"10.6004\/jnccn.2018.0002","article-title":"NCCN guidelines insights: multiple myeloma, version 3.2018","volume":"16","author":"Kumar","year":"2018","journal-title":"Journal of the National Comprehensive Cancer Network"},{"key":"10.1002\/14651858.CD013487-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/OTT.S123680","article-title":"Comparing efficacy and survivals of initial treatments for elderly patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials","volume":"10","author":"Liu","year":"2017","journal-title":"OncoTargets and Therapy"},{"issue":"6168","key":"10.1002\/14651858.CD013487-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"issue":"1","key":"10.1002\/14651858.CD013487-BIB0246|cit246","first-page":"212","article-title":"Fixed duration vs continuous therapy in multiple myeloma","volume":"Hematology 2017","author":"Ludwig","year":"2017","journal-title":"ASH Education Program"},{"key":"10.1002\/14651858.CD013487-BIB0247|cit247","unstructured":"GRADEpro Guideline Development Tool McMaster University (developed by Evidence Prime Available from www.gradepro.org 2015"},{"issue":"Supplement 3","key":"10.1002\/14651858.CD013487-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1188\/08.CJON.S1.13-19","article-title":"Myelosuppression associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board","volume":"12","author":"Miceli","year":"2008","journal-title":"Clinical Journal of Oncology Nursing"},{"issue":"7","key":"10.1002\/14651858.CD013487-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLOS Medicine"},{"issue":"5","key":"10.1002\/14651858.CD013487-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1182\/blood-2012-04-403733","article-title":"Proteasome inhibitors in multiple myeloma: 10 years later","volume":"120","author":"Moreau","year":"2012","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013487-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","article-title":"Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28 Suppl 4","author":"Moreau","year":"2017","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013487-BIB0252|cit252","unstructured":"National Cancer Institute Cancer stat facts: myeloma https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html"},{"key":"10.1002\/14651858.CD013487-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2147\/CMAR.S126136","article-title":"Multiple myeloma in Niger Delta, Nigeria: complications and the outcome of palliative interventions","volume":"9","author":"Nwabuko","year":"2017","journal-title":"Cancer Management and Research"},{"issue":"10","key":"10.1002\/14651858.CD013487-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2004-02-0408","article-title":"Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial","volume":"104","author":"Palumbo","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD013487-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"issue":"11","key":"10.1002\/14651858.CD013487-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013487-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3324\/haematol.2012.067058","article-title":"Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials","volume":"98","author":"Palumbo","year":"2013","journal-title":"Haematologica"},{"issue":"24","key":"10.1002\/14651858.CD013487-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD013487-BIB0259|cit259","first-page":"g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ (Clinical research ed.)"},{"issue":"1","key":"10.1002\/14651858.CD013487-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"key":"10.1002\/14651858.CD013487-BIB0261|cit261","unstructured":"R Foundation for Statistical Computing R: A language and environment for statistical computing R Core Team 2018"},{"issue":"12","key":"10.1002\/14651858.CD013487-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD013487-BIB0263|cit263","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 2014"},{"issue":"8","key":"10.1002\/14651858.CD013487-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1080\/14737140.2018.1490181","article-title":"Maintenance and continuous therapy for multiple myeloma","volume":"18","author":"Richardson","year":"2018","journal-title":"Expert Review of Anticancer Therapy"},{"issue":"4","key":"10.1002\/14651858.CD013487-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/jrsm.1058","article-title":"Network meta-analysis, electrical networks and graph theory","volume":"3","author":"R\u00fccker","year":"2012","journal-title":"Research Synthesis Methods"},{"issue":"25","key":"10.1002\/14651858.CD013487-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1002\/sim.6236","article-title":"Reduce dimension or reduce weights? Comparing two approaches to multi-arm studies in network meta-analysis","volume":"33","author":"R\u00fccker","year":"2014","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD013487-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD013487-BIB0268|cit268","unstructured":"http:\/\/CRAN.R-project.org\/package=netmeta netmeta: Network Meta-Analysis using Frequentist Methods. R package version 0.9-8 R\u00fccker G Schwarzer G Krahn U K\u00f6nig J 2018"},{"issue":"4","key":"10.1002\/14651858.CD013487-BIB0269|cit269","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1200\/JCO.2012.41.6180","article-title":"Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma","volume":"31","author":"San Miguel","year":"2013","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013487-BIB0270|cit270","volume-title":"netmeta: Network Meta-Analysis using Frequentist Methods","author":"Schwarzer","year":"2015"},{"key":"10.1002\/14651858.CD013487-BIB0271|cit271","unstructured":"http:\/\/CRAN.R-project.org\/package=meta meta: General Package for Meta-Analysis. R package version 4.9-2 Schwarzer G 2018"},{"key":"10.1002\/14651858.CD013487-BIB0272|cit272","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and 'Summary of findings tables'. In: Higgins JP Green S (editors). Cochrane Handbook of Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD013487-BIB0273|cit273","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JP Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S editor(s). Cochrane Handbook of Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD013487-BIB0274|cit274","unstructured":"Sch\u00fcnemann HJ Higgins JPT Vist GE Glasziou P Akl AE Skoetz N Guyatt GH Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions London Cochrane"},{"issue":"21","key":"10.1002\/14651858.CD013487-BIB0275|cit275","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013487-BIB0276|cit276","unstructured":"Sterne JA Egger M Chapter 10: Addressing reporting biases. In: Higgins JP, Green S, editor(s). Cochrane Handbook of Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD013487-BIB0277|cit277","doi-asserted-by":"crossref","unstructured":"Taplitz RA Kennedy EB Bow EJ Crews J Gleason C Hawley DK Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update Journal of Clinical Oncology 2018 36 30 3043 54","DOI":"10.1200\/JCO.18.00374"},{"key":"10.1002\/14651858.CD013487-BIB0278|cit278","unstructured":"The American Cancer Society Signs and symptoms of multiple myeloma https:\/\/www.cancer.org\/cancer\/multiple-myeloma\/detection-diagnosis-staging\/signs-symptoms.html"},{"key":"10.1002\/14651858.CD013487-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"25","key":"10.1002\/14651858.CD013487-BIB0280|cit280","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1182\/blood-2010-07-298760","article-title":"Racial disparities in incidence and outcome in multiple myeloma: a population-based study","volume":"116","author":"Waxman","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD013487-BIB0281|cit281","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/10428194.2016.1177772","article-title":"A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation","volume":"58","author":"Weisel","year":"2017","journal-title":"Leukemia & Lymphoma"},{"issue":"1","key":"10.1002\/14651858.CD013487-BIB0282|cit282","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1529-8027.2008.00156.x","article-title":"Chemotherapy-induced neuropathy","volume":"13","author":"Windebank","year":"2008","journal-title":"Journal of the Peripheral Nervous System"},{"key":"10.1002\/14651858.CD013487-BIB0283|cit283","unstructured":"World Health Organization WHO updates global guidance on medicines and diagnostic tests to address health challenges, prioritize highly effective therapeutics, and improve affordable access. Available at: https:\/\/www.who.int\/news-room\/detail\/09-07-2019-who-updates-global-guidance-on-medicines-and-diagnostic-tests-to-address-health-challenges-prioritize-highly-effective-therapeutics-and-improve-affordable-access (accessed: 30 August 2019) 2019"},{"key":"10.1002\/14651858.CD013487-BIB0284|cit284","unstructured":"World Health Organization Executive Summary. The Selection and Use of Essential Medicines 2019. Report of the 22nd WHO Expert Committee on the 2019 Selection and Use of Essential Medicines. Available at: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/325773\/WHO-MVP-EMP-IAU-2019.05-eng.pdf?ua=1 (accessed 30 August 2019)"},{"key":"10.1002\/14651858.CD013487-BIB0285|cit285","unstructured":"Piechotta V Jakob T Scheckel B Langer P Monsef I Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis PROSPERO"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD013487\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T08:06:49Z","timestamp":1680768409000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013487"}},"subtitle":[],"editor":[{"name":"Cochrane Haematology Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,11,25]]},"references-count":285,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013487","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,25]]}}}